SCHEMBL2761530

SCHEMBL2761530

CCOC(=O)CNC(=O)c1c(O)c2ccc(Br)cc2oc1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
CA12 O43570 3/20 0.46
CA9 Q16790 3/20 0.46
EGLN1 Q9GZT9 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MAPT P10636 2/20 0.44
VKORC1 Q9BQB6 1/20 0.43
GLA P06280 3/20 0.43
KDM4E B2RXH2 2/20 0.43
CASP1 P29466 2/20 0.43
CASP7 P55210 2/20 0.43
HSD17B10 Q99714 2/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
TBK1 Q9UHD2 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762563 0.89 KMT2A (0.51) ALDH1A1SMN1; SMN2MAPTVKORC1GLA
SCHEMBL11933976 0.87 EGLN1 (0.47) ALDH1A1CA12CA9EGLN1HPGD
SCHEMBL2761386 0.84 EGLN1 (0.58) CA12CA9EGLN1
SCHEMBL2761686 0.76 CA12 (0.57) ALDH1A1CA12CA9MAPTKDM4E
SCHEMBL2383982 0.75 EGLN1 (0.62) ALDH1A1EGLN1SMN1; SMN2KDM4EGAA
SCHEMBL2761937 0.75 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2MAPTGLAKDM4E
SCHEMBL2761719 0.75 EGLN1 (0.46) EGLN1MEN1KMT2ATDP1
SCHEMBL2762160 0.75 CA12 (0.62) CA12CA9EGLN1
SCHEMBL9204225 0.74 CA12 (0.51) ALDH1A1CA12CA9SMN1; SMN2MAPT
SCHEMBL2781241 0.74 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2MAPTGLAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 US disclosed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 ALDH1A1 202/4885CA12 783/4885CA9 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.